Finance

Lists
KROS:NASDAQ
Keros Therapeutics Inc
$9.42
+0.64%
(+0.060) 1D
Nov 9, 3:16:18 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
$9.50
High
$9.87
Low
$9.31
Mkt. cap
186.77M
Avg. vol.
164.30K
Volume
77.47K
52-wk high
$22.55
52-wk low
$9.26
EPS
-$2.83
Beta
1.13
Shares outstanding
19.62M
No. of employees
87
Open
$9.50
High
$9.87
Low
$9.31
Mkt. cap
186.77M
Avg. vol.
164.30K
Volume
77.47K
52-wk high
$22.55
52-wk low
$9.26
EPS
-$2.83
Beta
1.13
Shares outstanding
19.62M
No. of employees
87
News stories
From web sources and news partners
About Keros Therapeutics Inc
CEO-
Employees87
Founded2015
HeadquartersLexington, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitekerostx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current $9.42
$20.00 (+112.31%)
Average
$17.75 (+88.43%)
Lowest
$16.00 (+69.85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yun Zhong
Wedbush
Hold
Maintained
$16.00
+69.9%
11/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$20.00
+112.3%
11/06/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$18.00
+91.1%
09/02/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
$17.00
+80.5%
08/11/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/04/2026
Thomas Smith
Leerink Partners
Buy
Maintained
$23.00
+144.2%
08/04/2026
Nicholas Lorusso
TD Cowen
Hold
Reiterated
-
-
08/04/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$27.00
+186.6%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$30.00
+218.5%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
$20.00
+112.3%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
385.00K
367.00K
-
40.01M
Cost of goods sold
17.81M
16.10M
22.33M
-
Cost of revenue
17.81M
16.10M
22.33M
-
Research and development expenses
-
-
-
20.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.74M
10.15M
8.61M
6.70M
Operating expense
11.74M
10.15M
8.61M
27.19M
Total operating expenses
29.56M
26.24M
30.94M
27.19M
Operating income
-29.17M
-25.88M
-30.94M
12.82M
Other non operating income
-539.00K
-
-60.00K
-168.00K
EBT including unusual items
-24.98M
-23.71M
-28.71M
14.92M
EBT excluding unusual items
-24.88M
-23.71M
-28.71M
14.92M
Income tax expense
-1.51M
-
-
772.00K
Effective tax rate
6.06%
-
-
5.17%
Other operating expenses
-
-
-
-
Net income
-23.46M
-23.71M
-28.71M
14.15M
Net profit margin
-6,093.77%
-6,459.95%
-
35.37%
Earnings per share
-0.86
-1.21
-1.45
0.70
Interest and investment income
4.02M
2.34M
2.29M
2.28M
Interest expense
-
-
-
-
Net interest expenses
4.02M
2.34M
2.29M
2.28M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.77M
-25.47M
-30.54M
13.20M
Gain or loss from assets sale
1.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps